Your browser doesn't support javascript.
loading
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller, Alex; Garrido, Ana; Guijarro, Francesca; Oñate, Guadalupe; Diaz-Beyá, Marina; Arnan, Montserrat; Tormo, Mar; Vives, Susana; de Llano, María Paz Queipo; Coll, Rosa; Gallardo, David; Vall-Llovera, Ferran; Escoda, Lourdes; Garcia-Guiñon, Antonio; Salamero, Olga; Sampol, Antònia; Merchan, Brayan M; Bargay, Joan; Castaño-Díez, Sandra; Esteban, Daniel; Oliver-Caldés, Aina; Rivero, Andrea; Mozas, Pablo; López-Guerra, Mònica; Pratcorona, Marta; Zamora, Lurdes; Costa, Dolors; Rozman, Maria; Nomdedéu, Josep F; Colomer, Dolors; Brunet, Salut; Sierra, Jorge; Esteve, Jordi.
Afiliação
  • Bataller A; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Garrido A; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Guijarro F; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Oñate G; Hematology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Diaz-Beyá M; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Arnan M; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Tormo M; Hematology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Vives S; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • de Llano MPQ; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain.
  • Coll R; Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Gallardo D; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain.
  • Vall-Llovera F; Hematology Department, Hospital Virgen de la Victoria, Málaga, Spain.
  • Escoda L; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Universitari Dr. Josep Trueta, Girona, Spain.
  • Garcia-Guiñon A; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Universitari Dr. Josep Trueta, Girona, Spain.
  • Salamero O; Hematology Department, Hospital Universitari Mútua de Terrassa, Terrassa, Spain.
  • Sampol A; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Universitari Joan XXIII, Tarragona, Spain.
  • Merchan BM; Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain.
  • Bargay J; Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Castaño-Díez S; Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Esteban D; Hematology Department, Hospital del Mar, Barcelona, Spain.
  • Oliver-Caldés A; Hematology Department, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain.
  • Rivero A; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Mozas P; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • López-Guerra M; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Pratcorona M; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Zamora L; Hematology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain.
  • Costa D; Hematopathology Section, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain; and.
  • Rozman M; Centro de Investigación Biomédica en Red en Oncología, Madrid, Spain.
  • Nomdedéu JF; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Colomer D; Hematology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Brunet S; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Sierra J; Hematology Department, Catalan Institute of Oncology (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain.
  • Esteve J; Hematopathology Section, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona (UB), Barcelona, Spain; and.
Blood Adv ; 6(4): 1193-1206, 2022 02 22.
Article em En | MEDLINE | ID: mdl-34911079
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha